Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

TG SAFE suspends FSSAI licenses of nine food establishments in Hyderabad for food safety violations

Officials identified multiple food safety violations, including spoilt and contaminated meat and vegetables, pest infestations, unhygienic conditions, expired products, and poor record maintenance

TG SAFE suspends FSSAI licenses of nine food establishments in Hyderabad for food safety violations

The Telangana Standards Authority for Food and Essential Drugs (TG SAFE) has suspended the FSSAI licenses of nine food establishments in Hyderabad's LB Nagar area following a special enforcement drive on September 16, 2026. The drive, conducted by ten teams of Food Safety Officers and police personnel, inspected 20 restaurants, hotels, and manufacturing units.

Inspectors found various food safety violations, including spoiled and contaminated meat and vegetables, infestations of cockroaches, houseflies, and rodents, unhygienic premises, and expired food products. The establishments with suspended licenses include Hotel Sangeeth Grand Restaurant and Bar, Bahar Biryani Cafe, Balaji Pheni and Namkeen, Bhuvaneshwari Oil Industries, and others.

TG SAFE has ordered these establishments to cease operations immediately and will follow up with improvement notices and show-cause notices for non-compliance.

Brief written by urgent.news from The Hindu's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at thehindu.com →

More in Health & Medicine

Celltrion’s Remsima Takes No. 1 Spot in Japan’s Infliximab Market After 11 Years

Celltrion’s infliximab biosimilar Remsima has become the most prescribed infliximab product in Japan, 11 years after entering a market where biosimilars have traditionally faced limited price-driven…

  • Celltrion's Remsima leads Japan's infliximab market with 48% share since 2015
  • Remsima's success in Japan attributed to physicians' prescribing experience and sales capabilities
  • Celltrion plans to launch subcutaneous Remsima SC in Japan in 2027

More from Thursday 17 September →